Exane BNP Paribas analyst Miguel Borrega upgrades PACCAR (NASDAQ:PCAR) from Underperform to Neutral and raises the price target from $85 to $100.
Evolus Sees FY23 Revenue $180M-$190M
2023 Outlook and Long-Term Aspirations
"Based on our success to date and a fundamentally strong aesthetic neurotoxin market, we are projecting continued above-market growth for Evolus in 2023,"